Abeona Therapeutics(ABEO)
CLEVELAND, OH
BiotechnologyFocus: Therapies for Sanfilippo (SF) Syndrome Type A and Type B.
Abeona Therapeutics is a life sciences company focused on Therapies for Sanfilippo (SF) Syndrome Type A and Type B..
Funding Stage
PUBLIC
Employees
1001-5000
Open Jobs
0
Pipeline & Clinical Trials
EB-101
RDEBClinical Trials (1)
NCT05708677A Long-Term Extension Study for Participants Previously Treated With EB-101 for the Treatment of RDEB
N/AABO-101
Mucopolysaccharidosis III-BClinical Trials (1)
NCT04655911A Long-term Follow-up Study of Patients With MPS IIIB Treated With ABO-101
N/AABO-102
MPS IIIAClinical Trials (1)
NCT04088734Gene Transfer Study of ABO-102 in Patients With Middle and Advanced Phases of MPS IIIA Disease
Phase 1/2rAAV9.CMV.hNAGLU
Mucopolysaccharidosis Type 3 BClinical Trials (1)
NCT03315182Gene Transfer Clinical Trial for Mucopolysaccharidosis (MPS) IIIB
Phase 1/2LZRSE-Col7A1 Engineered Autologous Epidermal Sheets
Epidermolysis Bullosa DystrophicaClinical Trials (1)
NCT01263379Gene Transfer for Recessive Dystrophic Epidermolysis Bullosa
Phase 1/2EcoNailâ„¢
OnychomycosisClinical Trials (1)
NCT00385502A Trial of the Safety and Efficacy of EcoNailâ„¢ in the Treatment of Fungus Infections of the Great Toenail
Phase 2UX111
MPS IIIAClinical Trials (1)
NCT02716246Phase I/II/III Gene Transfer Clinical Trial of scAAV9.U1a.hSGSH
Phase 2/3ofloxacin
Diabetic Foot UlcersClinical Trials (1)
NCT00563394MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers
Phase 3EB-101
Epidermolysis BullosaClinical Trials (1)
NCT04227106Phase 3, Open-label Clinical Trial of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Phase 3ofloxacin
Diabetic Foot UlcersClinical Trials (1)
NCT00563433MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers
Phase 3EB-101 Surgical application of RDEB wounds
Epidermolysis BullosaClinical Trials (1)
NCT05725018A Phase 3b Study for the Treatment of Dystrophic Epidermolysis Bullosa (DEB) in New and Previously EB-101 Treated Patients
Phase 3Open Jobs (0)
No open positions listed yet. Check their careers page directly.
Interview Prep Quick Facts
Portfolio: 11 clinical trials
SEC Filings: 2 available
Financials (FY2024)
Revenue
$4M148%
R&D Spend
$31M(888%)7%
Net Income
-$54MCash
$14M